ClinicalTrials.gg
CompletedNCT06189508Updated Jan 15, 2025

A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

A Phase 1 interventional study of NXT007 in Healthy Male Participants, sponsored by Hoffmann-La Roche. Completed at 2 sites in New Zealand. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a Phase I, open-label, non-randomized, parallel-group, single-dose study in healthy adult male participants. The aim is to investigate the relative bioavailability (rBA) of NXT007 among subcutaneous (SC) injection sites (abdomen, upper arm, and thigh) and the absolute bioavailability (aBA) of SC NXT007 administration. In addition, the pharmacodynamic, safety, tolerability, and immunogenicity of a single dose of NXT007 following SC or intravenous (IV) administration are assessed.

02

Conditions studied

  • Healthy Male Participants
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy as determined by medical evaluation that includes medical history, physical examination, vital signs, laboratory tests, and 12-lead
  • (BMI) within the range of 18.5 to 30.0 kg/m\^2
  • Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, immunological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data
  • History of allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies; or known to any constituent of the product
  • medical history and/or family history or signs of thromboembolic disease such as deep vein thrombosis
  • FVIII activity ≥120 International Units per decilitre (IU/dL) at screening
  • Clinically significant abnormality on (ECG) at screening such as after 10-minute supine rest >450 milliseconds (ms); marked resting bradycardia (mean heart rate \<40 beats per minute [bpm]); marked resting tachycardia (mean heart rate >100 bpm); or any other clinically significant ECG abnormality
  • Supine systolic blood pressure at screening ≥140 millimetres of mercury (mm Hg) or \<90 mm Hg or supine diastolic blood pressure at screening ≥90 mm Hg or \<40 mm Hg
  • Clinically significant abnormality on protein C activity (chromogenic assay), activated protein C resistance test, protein S free antigen, and/or antithrombin III activity levels
  • Poor peripheral venous access
  • Any other reason that, in the judgment of the investigator, would render the participants unsuitable for study participation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    A: Single NXT007 SC Injection Into Abdomen

    Drug: NXT007

  • Experimental
    B: Single NXT007 SC Injection Into Upper Arm

    Drug: NXT007

  • Experimental
    C: Single NXT007 SC Injection Into Thigh

    Drug: NXT007

  • Experimental
    D: Single NXT007 IV Infusion

    Drug: NXT007

Interventions

  • DrugNXT007

    In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.

    Also known as: RO7589655

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) of NXT007

    Time frame: At prespecified timepoints from Day 1 until Day 253

  2. Maximum Observed Plasma Concentration (Cmax) of NXT007

    Time frame: At prespecified timepoints from Day 1 until Day 253

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve up to the Last Measurable Concentration (AUC0-last) of NXT007

    Time frame: At prespecified timepoints from Day 1 until Day 253

  2. Time to Maximum Observed Plasma Concentration (tmax) of NXT007

    Time frame: At prespecified timepoints from Day 1 until Day 253

  3. Apparent Terminal Half-Life (t1/2) of NXT007

    Time frame: At prespecified timepoints from Day 1 until Day 253

  4. Apparent Clearance (CL/F) of NXT007 SC Administration

    Time frame: At prespecified timepoints from Day 1 until Day 253

  5. Total Body Clearance (CL) of NXT007 IV Administration

    Time frame: At prespecified timepoints from Day 1 until Day 253

  6. Volume of Distribution at Steady State of NXT007 IV Administration

    Time frame: At prespecified timepoints from Day 1 until Day 253

  7. Incidence and Severity of Adverse Events

    Time frame: From the single dose of study treatment (Day 1) until study completion (Day 253)

  8. Number of Participants with Abnormal Laboratory Values in Clinical Chemistry Parameters

    Time frame: From the single dose of study treatment (Day 1) until study completion (Day 253)

  9. Number of Participants with Abnormal Laboratory Values in Hematology Parameters

    Time frame: From the single dose of study treatment (Day 1) until study completion (Day 253)

  10. Change from Baseline in Pulse Rate at Specified Timepoints

    Time frame: Baseline, Days 1, 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225, and 253

  11. Change from Baseline in Tympanic Temperature at Specified Timepoints

    Time frame: Baseline, Days 1, 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225, and 253

  12. Change from Baseline in Systolic Blood Pressure at Specified Timepoints

    Time frame: Baseline, Days 1, 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225, and 253

  13. Change from Baseline in Diastolic Blood Pressure at Specified Timepoints

    Time frame: Baseline, Days 1, 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225, and 253

  14. Change from Baseline in Heart Rate at Specified Timepoints, as Measured by Electrocardiogram

    Time frame: Baseline, Days 1, 2, 8, 22, 43, 71, 141, and 253

  15. Change from Baseline in RR, PR, QRS, QT, and QTcF Intervals at Specified Timepoints, as Measured by Electrocardiogram

    Time frame: Baseline, Days 1, 2, 8, 22, 43, 71, 141, and 253

  16. Change from Baseline in Activated Partial Thromboplastin Time (aPTT) at Specified Timepoints

    Time frame: Baseline, Days 1, 2, 8, 15, 18, 20, 22, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225, and 253

  17. Change from Baseline in the Maximum Concentration of Thrombin Generated at Specified Timepoints

    Time frame: Baseline, Days 1, 18, 20, and 22

  18. Prevalence of Anti-Drug Antibodies (ADAs) to NXT007 at Baseline and Incidence of ADAs to NXT007 During the Study

    Time frame: From Baseline until Day 253

07

Study locations

2 sites
  • New Zealand Clinical Research - Auckland
    Auckland, 1010, New Zealand
  • New Zealand Clinical Research - Christchurch
    Christchurch, 8011, New Zealand
08

References and documents

Individual participant data

Plan to share: No — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Dec 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Jan 3, 2024
StartActual
Feb 14, 2024
Primary completionActual
Dec 22, 2024
CompletionActual
Dec 22, 2024
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06189508
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Feb 14, 2024
Primary completion
Dec 22, 2024
Completion
Dec 22, 2024
Last update
Jan 15, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NXT007

Start the discussion